Abstract
A collateral sensitivity or a very modest cross-resistance to BBR 3464 was found in 2 ovarian cancer cell lines with experimentally induced resistance to cisplatin Loss of mismatch repair proteins (hMLH1, hPMS2) or overexpression of nucleotide excision repair proteins (ERCC1) was not detrimental for the cellular sensitivity to BBR 3464 Moreover, interesting differences in the kinetics of formation and removal of DNA lesions at the single-gene (N-ras) level were observed between BBR 3464 and CDDP.
| Original language | English |
|---|---|
| Pages (from-to) | 1387-1390 |
| Number of pages | 4 |
| Journal | British Journal of Cancer |
| Volume | 84 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - 18 May 2001 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- BBR 3464
- Cisplatin
- DNA repair
- Ovarian cancer
Fingerprint
Dive into the research topics of 'Activity of a trinuclear platinum complex in human ovarian cancer cell lines sensitive and resistant to cisplatin: Cytotoxicity and induction and gene-specific repair of DNA lesions'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver